Alterity Therapeutics Limited Appendix 4E - Preliminary Final Report For the year ended 30 June 2021 Name of entity Alterity Therapeutics Limited ABN or equivalent company reference 37 080 699 065 Current reporting perio

Alterity Therapeutics Limited

Appendix 4E - Preliminary

For the year ended 30 June 2021

Results for announcement to the market

Net tangible assets per share

Explanation of results

Alterity Therapeutics Limited recorded

revenue of $20,676 for the year ended 30 June 2021 (2020: $17,117), which is interest received on the Group's bank accounts. Alterity

Therapeutics Limited has incurred a loss for the year of $15,309,353 (2020: $13,456,800). T his loss has increased due to the increased

research and development expenditure relating to the preparation for the Phase 2 study of Group's lead product candidate ATH434.

For further details relating to the current period's

results, refer to the Review of operations and activities contained within this document.

Changes in controlled entities

Other information required by Listing Rule 4.3A

These accounts have been audited. An unmodified audit report

is provided with the accompanying financial report.

Alterity Therapeutics Limited

Annual report - 30 June 2021

Copyright Alterity Therapeutics.

Therapeutics Limited

Report June 30, 2021

I'm pleased to present this year's Annual

Report which we have combined with our SEC Form 20-F annual report. It has been a significant year for Alterity and for me personally

as I handed the CEO reigns to Dr David Stamler and assumed the role of Non-Executive Chair in January 2021. As our company evolves, so

too should our leadership and Dr Stamler was a strong and natural choice. He joined Alterity in June 2017 as Chief Medical Officer and

Senior Vice President Clinical Development and has partnered with me on presenting our compelling scientific, clinical, and corporate

opportunity to the world. Dr Stamler brings a deep understanding of the diseases we are seeking to cure, the science that supports our

hypothesis, and an outstanding track record in bringing new drugs to market.

Our opportunity is big, and we are motivated by our

purpose to give people living with debilitating neurodegenerative diseases an alternate future. A future where our therapies change the

course of their disease, treat their symptoms, and significantly improve both quality and duration of life. We are seeing the convergence

of several big themes. Treatments for the underlying causes of the ageing mind like Alzheimer's disease have eluded scientists,

clinicians, and big pharma. However, we are starting to see progress and recent drug approvals that give hope to the large populations

around the world who will develop these diseases in the future. True also for other neurodegenerative diseases, such as Parkinsonian disorders

on which we are focused, that have no cure, few treatments of symptoms, and are debilitating. The need for treatments that can alter the

future for these patients has never been greater and this remains an important ambition for Alterity.

Alterity's science targets misfolding and aggregating

proteins and places us at the intersection of these neurodegenerative diseases. Our lead compound ATH434 has shown that it inhibits the

aggregation of pathological proteins implicated in important diseases. It reduces abnormal accumulation proteins in the brain and by binding

and redistributing iron to restore brain function. In this way, it has potential to treat Parkinson's disease and atypical forms

of Parkinsonism such as Multiple System Atrophy (MSA) - our first indication. These same metals and proteins have also been implicated

in certain forms of dementia.

Whilst the opportunity for our therapies is only growing,

we remain highly focused on the current goal to advance ATH434 to a Phase 2 study later this calendar year. We continue to collect vital

observational data in our natural history study of MSA, BioMUSE, which has exceeded its original enrollment goals and has been expanded.

These data have allowed us to understand how the disease behaves in our target patient population so we can optimize the design our Phase

2 trial related to patient population and endpoints, and thereby maximizing the chance of success.

Therapeutics Limited

Report June 30, 2021

Our scientific hypothesis is gaining acceptance and

pace with scientific audiences, and we were invited to present our data at pre-eminent scientific and clinical conferences throughout

the year. These conferences gather the world's leading authorities in neurodegenerative disease, all sharing a common goal to enable

a new generation of improved treatments for patients.

We expanded our intellectual property portfolio with two

new US patents that cover novel pharmaceutical compositions that are designed to redistribute the labile iron implicated in many neurodegenerative

conditions including Alzheimer's and Parkinson's. This is important as we start to look to future opportunities for Alterity

and expand our portfolio of potential disease modifying treatments for neurodegenerative diseases affecting many individuals.

We are also continuing to engage closely with regulators

around the world as we near the commencement of the multi-country, multi-site Phase 2 trial. Most recently we received guidance from the

European Medicines Agency (EMA) regarding key aspects of the trial. The EMA provides an important role in supporting the timely and sound

development of high-quality, effective, and safe medicines, for the benefit of patients.

Given there is no approved treatment for MSA, there

is currently no regulatory precedence for defining the most suitable patient population or clinical endpoints in efficacy studies, thus

requiring greater consideration in developing an optimal trial design. The EMA has given its support to Alterity's intention to

enroll early-stage MSA patients and to utilize biomarkers to accurately diagnose these patients prior to enrolment. Improving diagnostic

accuracy and targeting early-stage patients will enable Alterity to maximize the opportunity to demonstrate the efficacy of ATH434, its

potentially disease modifying therapy.

We were also well supported by the investment community

in both Australia and the United States in raising capital to support the conduct of the Phase 2 clinical trial. We thank our new and

existing shareholders for their support as we head towards this important milestone. Finally, on behalf of the Board, I'd like to

thank Dr Stamler and his executive team, and all our scientific and operational staff and partners for their efforts over the last year.

We have an aligned purpose and whilst our steps forward might sometimes seem small, they are all important in moving forward to a position

where we can give hope to patients and families for an alternate future.

SECURITIES AND EXCHANGE

Washington D.C. 20549

year ended June 30, 2021

period from __________ to __________

Date of event requiring

this shell company report ___________

Commission file number 000-49843

ALTERITY THERAPEUTICS LIMITED

(Exact name of Registrant as

specified in its charter

and translation of Registrant's

(Jurisdiction of incorporation

Level 3, 460 Bourke Street,

Melbourne, VIC 3000, Australia

(Address of principal executive

David Stamler, Chief Executive

Level 3, 460 Bourke Street, Melbourne, VIC 3000,

+61 3 9349 4906 (phone) ;

+61 3 9348 0377 (fax)

(Name, telephone, e-mail and/or facsimile number

and address of company contact person)

Securities registered